QVAR 40
Clinical safety rating: caution
Comprehensive clinical and safety monograph for QVAR 40 (QVAR 40).
Beclomethasone dipropionate is a corticosteroid with potent anti-inflammatory activity. It binds to glucocorticoid receptors, leading to modulation of gene expression and inhibition of inflammatory mediators such as cytokines, leukotrienes, and prostaglandins. It reduces airway hyperresponsiveness and inflammation.
| Metabolism | Beclomethasone dipropionate is metabolized primarily by esterase enzymes to the active metabolite beclomethasone-17-monopropionate, which is further metabolized by CYP3A4 to inactive metabolites. |
| Excretion | Primarily hepatic metabolism via CYP3A4, with inactive metabolites excreted in feces (approximately 60-70%) and urine (30-40%). Less than 10% excreted unchanged. |
| Half-life | Terminal elimination half-life is approximately 2.9 hours in adults after inhalation, reflecting rapid clearance from plasma. |
| Protein binding | 98% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Vd is approximately 0.6 L/kg, indicating distribution into total body water. |
| Bioavailability | Inhalation: absolute bioavailability is approximately 22% of the nominal dose due to deposition in the lungs and gastrointestinal tract; oral bioavailability is less than 1% due to extensive first-pass metabolism. |
| Onset of Action | Inhalation: 24 hours for clinical improvement in asthma symptoms; maximal effect observed after 1-2 weeks of regular use. |
| Duration of Action | Duration of action is 12 hours after a single dose, supporting twice-daily dosing for maintenance therapy. |
| Molecular Weight | 521.05 |
| Action Class | Inhaled Corticosteroid |
40-160 mcg inhaled twice daily for asthma maintenance; maximum 320 mcg/day.
| Dosage form | AEROSOL, METERED |
| Renal impairment | No dose adjustment required; pharmacokinetics not significantly altered in renal impairment. |
| Liver impairment | No specific Child-Pugh based guidelines; use with caution in severe hepatic impairment due to potential increased systemic exposure. |
| Pediatric use | Children 5-11 years: 40-80 mcg inhaled twice daily; maximum 160 mcg/day. Children 12 years and older: same as adult. |
| Geriatric use | Start at lower end of dosing range (40 mcg twice daily); monitor for local adverse effects; no specific dose adjustment required based on age alone. |
| 1st trimester | Inhaled beclomethasone dipropionate is preferred for asthma during pregnancy; no increased risk of major malformations across trimesters. |
| 2nd trimester | Use if benefit outweighs risk; monitor for potential growth restriction and maternal glucose. |
| 3rd trimester | Use if indicated; consider potential for neonatal adrenal suppression if high doses near term. |
Clinical note
Comprehensive clinical and safety monograph for QVAR 40 (QVAR 40).
| Placental transfer | Beclomethasone dipropionate crosses placenta; active metabolite beclomethasone-17-monopropionate has higher transfer. Fetal exposure is lower with inhaled route compared to systemic administration. |
| Breastfeeding | Low systemic absorption; minimal excretion into breast milk. Compatible with breastfeeding according to AAP and ACAAI. Risk to infant unlikely. |
■ FDA Black Box Warning
None
| Common Effects | Headache, Pharyngitis, Sinusitis, Cough, Dysphonia, Throat irritation |
| Serious Effects | Adrenal insufficiency (with prolonged use or high doses), Oropharyngeal candidiasis, Paradoxical bronchospasm, Reduced bone mineral density (with long-term use), Glaucoma and cataracts (with long-term use), Growth suppression in children |
Hypersensitivity to beclomethasone dipropionate or any excipientStatus asthmaticus (not for acute severe asthma)
| Precautions | Localized oral and pharyngeal infections with Candida albicans; paradoxical bronchospasm; hypothalamic-pituitary-adrenal axis suppression with excessive doses; reduction in growth velocity in children; need to switch to systemic corticosteroids during stress or severe asthma exacerbation; careful monitoring for patients with systemic corticosteroid withdrawal; potential for eosinophilic conditions; avoiding use in patients with active or quiescent tuberculosis, untreated fungal, bacterial, or viral infections, or ocular herpes simplex. |
Loading safety data…
| Lactation Rating | L1 - Safe |
| Teratogenic Risk | QVAR 40 (beclomethasone dipropionate) is an inhaled corticosteroid. Based on human data from large cohort studies and meta-analyses, inhaled corticosteroids at recommended doses are not associated with a significant increase in major congenital malformations. However, there is a potential risk of reduced fetal growth and low birth weight with high doses. First trimester: no clear teratogenic risk. Second and third trimesters: risk of intrauterine growth restriction (IUGR) and adrenal suppression in the fetus if maternal use is prolonged at high doses. |
| Fetal Monitoring | Monitor maternal asthma control (peak expiratory flow, symptoms, exacerbations). For fetal growth, consider serial ultrasound assessments of fetal growth in women requiring high doses or with severe asthma. Monitor for maternal adrenal insufficiency if prolonged high-dose therapy is used. No specific fetal monitoring required at standard doses. |
| Fertility Effects | No known adverse effects on fertility in humans. Animal studies show no impairment of fertility at inhaled doses up to 10 times the maximum recommended human daily inhalation dose. Asthma control itself is important for reproductive outcomes. |
| Food/Dietary | No significant food interactions. Avoid grapefruit juice as it may increase systemic exposure via CYP3A4 inhibition. |
| Clinical Pearls | QVAR 40 (beclomethasone dipropionate HFA) is a metered-dose inhaler delivering 40 mcg per actuation. It is used for maintenance treatment of asthma as prophylactic therapy. Rinse mouth with water after each use to reduce risk of oropharyngeal candidiasis. Not indicated for acute bronchospasm. Monitor for adrenal insufficiency during stress or prolonged use. Shake well before each use. Use a spacer device to improve lung deposition and reduce oropharyngeal side effects. |
| Patient Advice | Do not use QVAR 40 for acute asthma attacks; use a rescue inhaler (e.g., albuterol) instead. · Rinse your mouth with water and spit after each use to prevent thrush. · Use regularly as prescribed, even if you feel well, to control asthma. · Prime the inhaler before first use or if not used for more than 10 days. · Track your asthma symptoms and peak flow; seek medical help if symptoms worsen. · Avoid smoking and exposure to irritants; get the influenza vaccine annually. |